Pharmaceutical marketing segmentation in the age of the Internet

Journal of Medical Marketing: Device, Diagnostic and Pharmaceutical Marketing

Volumn 2, Issue 2, 2002, Pages 159-166

  Lerer, Leonard ^a  

^a INSEAD   (France)

Author keywords

customer relationship management; Internet; market segmentation; pharmaceutical e business; segmentation

Indexed keywords

EID: 84990359461     PISSN: 17457904     EISSN: 17457912     Source Type: Journal    
DOI: 10.1057/palgrave.jmm.5040069     Document Type: Article

References (39)

1. Cjorstens M. (1991) Marketing Strategy in the Pharmaceutical Industry. London and New York: Chapman and Hall.
2. MacLennan J. MacKenzie D. (2000) ‘Strategic market segmentation: An opportunity to integrate medical and marketing opportunities’, International Journal of Medical Marketing 1(1), 40–52.
3. McDonald M. Dunbar I. (1988) Market Segmentation. London: Macmillan.
4. Smith W. (1956) ‘Product differentiation and market segmentation as alternative marketing strategies’, Journal of Marketing, 21 (3-8 July), 5.
5. Kuenne C. Choi L. (2000) ‘Segment-based marketing: From dream to reality’, Pharmaceutical Executive, October, 54–68.
6. MacLennan J. MacKenzie D. (2000) Pharmaceutical Executive.
7. Forrester Research Inc. (2001) Keeping Customers Loyal. New York: Forrester Research Inc.
8. Wind Y. (1978) ‘Issues and advances in segmentation research’, Journal of Marketing Research, XV(August).
9. Kuenne C. Choi L. (2000) Journal of Marketing Research.
10. Forsyth J. Gupta S. Haldar S., et al(1999) ‘A segmentation you can act on’, The McKinsey Quarterly, 3, 7–15.
11. Hutt E. Le Brun R. Mannhardt T. (2001) ‘Simplifying web segmentation’, The McKinsey Quarterly, 3, 12–18.
12. INSEAD and Cap Gemini/Ernst and Young (2001) Vision and Reality – The Quantum Shuffle: The impact of e on the pharmaceutical and medical device industries. London: INSEAD/CGEY.
13. Cain M. Sarasohn-Kahn J. Wayne J. (2001) Health e-People: The Online Consumer Experience. Los Angeles, Institute for the Future for the California Health Foundation.
14. Kohn L. Corrigan J. Donaldson M. (1999) To Err Is Human: Building a Safer Health System. Washington DC: National Academy Press.
15. Weed L. (1999) ‘Opening the black box of clinical judgement – an overview’, British Medical Journal, 319, 1–4.
16. Kreuter M. Farrell D.W. Olevitch L., et al(1999) Tailoring Health Messages. Chicago: Lawrence Erlbaum Associates.
17. McDonald M. Dunbar I. (1998) Tailoring Health Messages.
18. Cap Gemini/Ernst and Young (2000) Patient Relationship Management: The Patient's Role in the Life Sciences Industry. London: Cap Gemini/Ernst & Young.
19. Anand G. (2001) ‘Big drug companies try to delay ‘personalised’ medicine regimes’, in The Wall Street Journal.
20. ePHARM 5 (2001) Claritin Website Figures in Lawsuit against Schering-Plough. New York: Medical Broadcasting Company.
21. Firn D. (2001) Suitable cases for treatment, in Financial Times.
22. Jones M.I. Greenfield S. M. Bradley C.P. (2001) ‘Prescribing new drugs: qualitative study of influences on consultants and general practitioners’, British Medical Journal, 323(7309), 378.
23. PWC (1999) Pharma 2005: Marketing to the Individual. London: PriceWaterhouse Coopers.
24. Boston Consulting Group (2000) Getting Real about E-Health. Boston: The Boston Consulting Group.
25. Kreuter M., et al (1999) Getting Real about E-Health, Boston: The Boston Consulting Group
26. INSEAD and Cap Gemini/Ernst and Young (2001) Getting Real about E-Health.
27. Lerer L. Piper M. Harrison M., et al(2001) Pharma2015: The Future of Customer-focus and Customer-value in the Pharmaceutical Industry. Fontainebleau/London, INSEAD/Andersen.
28. ePHARM5 (2000) Adding an e-Commerce and Sampling Arm to the Site will allow P&G to Promote new Products to its Most Loyal Customers. New York: Medical Broadcasting Company.
29. Herzlinger R. (1997) Market-driven Health Care. Reading, Mass: Addison-Wesley.
30. Neuberger J. (1999) ‘Let's do away with “patients”’. British Medical Journal, 318, 1756–1757.
31. Bell R. Wilkes M. Kravitz R. (1999) ‘Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses’, Journal of Family Practice, 48, 446–452.
32. Wilkes M. Bell R. Kravitz R. (2000) ‘Direct-to-consumer prescription drug advertising: trends, impact, and implications’. Health Affairs, 19, 120–128.
33. Stern B.B. Thompson C. J. Arnould E. J. (1998) ‘Narrative analysis of a marketing relationship: The consumer's perspective’. Psychology & Marketing, 15(3), 195–214.
34. Cravey A. J. Washburn S.A. Gesler W., et al(2001) ‘Developing socio-spatial knowledge networks: a qualitative methodology for chronic disease prevention’. Social Science & Medicine, 52(12), 1763–75.
35. Knight K. Ives J. (2001) ‘Opinion leader development: A neglected area’. International Journal of Medical Marketing, 1(2), 142–147.
36. Haley R. (1968) ‘Benefit Segmentation: A decision – oriented tool’. Journal of Marketing, 32, 30–35.
37. Binkley C. (2000) ‘Casino chain hits pay dirt as it mines data on gamblers’, in Wall Street Journal. A1.
38. Lerer L., et al(2001) Wall Street Journal.
39. Gladwell M. (2000) The Tipping Point. London: Little Brown & Co.